Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413398 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
NCT02413398 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 321 participants.
The verdict
NCT02413398, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at approximately 100 centres from countries across North America and European regions. It is planned to randomize a total of 302 patients.
Interventions
- DRUG Dapagliflozin 10 mg
- DRUG Matching Placebo for Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2015-06-15 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413398
The ClinicalTrials.gov registry entry for NCT02413398 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin 10 mg is the first listed.
NCT02413398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02413398 about?
NCT02413398 is a clinical study titled "A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes". The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at approximately 100 centres from countries across North America and European regi...
What is the current status of trial NCT02413398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2015-06-15. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT02413398?
The interventions under investigation include: Dapagliflozin 10 mg (DRUG), Matching Placebo for Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02413398?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.